gene

MET

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about MET: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

644Connections

30Hypotheses

0Analyses

50Outgoing

50Incoming

10Experiments

0Debates

Summary

Page for MET - MET Proto-Oncogene, Receptor Tyrosine Kinase

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	MET
Aliases	Page for MET, c-Met
Chromosome	7q31.2
Protein Type	Receptor
Function	is a receptor tyrosine kinase (RTK) that plays crucial roles in embryonic development, tissue regeneration, and adult tissue homeostasis.
Molecular Weight	140 kDa
Amino Acids	1390 aa
Exons	21
Pathways	Key Effectors
GeneCards	MET
Human Protein Atlas	MET
Associated Diseases	AD, Aging, ALI, Als, Alzheimer, AMI
Known Drugs/Compounds	metformin, PLB-1001, resveratrol
Interactions	AKT, ALS, ALZHEIMER, ALZHEIMER'S DISEASE, AMPK, AMYLOID
KG Connections	644 knowledge graph edges
Databases	GeneCards UniProt NCBI Gene HPA STRING

Wiki Pages (6)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    MET["MET"] -->|"associated"| glioblastoma["glioblastoma"]
    MET["MET"] -->|"activates"| glioma_progression["glioma progression"]
    MET["MET"] -->|"biomarker for"| secondary_glioblastoma["secondary glioblastoma"]
    MET["MET"] -->|"therapeutic target"| Cancer["Cancer"]
    MET["MET"] -->|"expressed in"| Carcinoma["Carcinoma"]
    MET["MET"] -->|"therapeutic target"| Ms["Ms"]
    PTPRZ1["PTPRZ1"] -->|"interacts"| MET["MET"]
    PLB_1001["PLB-1001"] -.->|"inhibits"| MET["MET"]
    IDH1["IDH1"] -->|"therapeutic target"| MET["MET"]
    VEGFA["VEGFA"] -->|"therapeutic target"| MET["MET"]
    style MET fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (403)

Target	Relation	Type	Str
Als	therapeutic_target	disease	1.00
Cancer	therapeutic_target	disease	1.00
acquired resistance	promotes	phenotype	0.90
Inflammation	therapeutic_target	disease	0.85
Alzheimer's Disease	downregulates	disease	0.85
Als	associated_with	disease	0.85
Inflammation	associated_with	disease	0.85
MET Signaling	regulates	pathway	0.85
GSK3B	regulates	protein	0.80
Stroke	therapeutic_target	disease	0.75
Depression	associated_with	disease	0.75
Neuroinflammation	therapeutic_target	disease	0.75
Cancer	associated_with	disease	0.75
Carcinoma	activates	disease	0.75
Neurodegeneration	therapeutic_target	disease	0.75
Tumor	regulates	disease	0.75
Parkinson	therapeutic_target	disease	0.75
Diabetes	therapeutic_target	disease	0.75
Tumor	activates	disease	0.75
Tumor	inhibits	disease	0.75
Glioblastoma	therapeutic_target	disease	0.75
Alzheimer	therapeutic_target	disease	0.75
endothelial cells	expressed_in	cell_type	0.75
Cancer	regulates	disease	0.75
Infection	activates	disease	0.75
Schizophrenia	associated_with	disease	0.75
Als	activates	disease	0.75
Cancer	activates	disease	0.75
Fibrosis	activates	disease	0.75
Stem Cell	therapeutic_target	pathway	0.70
Mtor	therapeutic_target	pathway	0.70
glioblastoma	associated_with	disease	0.70
Autophagy	activates	pathway	0.70
Apoptosis	activates	pathway	0.70
secondary glioblastoma	biomarker_for	disease	0.70
Mapk	activates	pathway	0.70
Wnt signaling	participates_in	pathway	0.70
Oxidative Stress	therapeutic_target	pathway	0.70
Mapk	regulates	pathway	0.70
glioma progression	activates	process	0.70
Oxidative Stress	associated_with	pathway	0.70
Obesity	associated_with	disease	0.65
Cardiovascular	associated_with	disease	0.65
Tumor	associated_with	disease	0.65
Aging	therapeutic_target	disease	0.65
Amyotrophic Lateral Sclerosis	therapeutic_target	disease	0.65
Ms	regulates	disease	0.65
Carcinoma	therapeutic_target	disease	0.65
Lung Cancer	causes	disease	0.65
Coronary Artery Disease	associated_with	disease	0.65

Incoming (241)

Source	Relation	Type	Str
EGFR	interacts_with	gene	0.90
CANCER	therapeutic_target	gene	0.90
PI3K	activates	gene	0.90
Circular RNA	associated_with	biological_process	0.80
AKT	activates	gene	0.80
EGFR	inhibits	gene	0.80
OXIDATIVE STRESS	associated_with	gene	0.70
STROKE	therapeutic_target	gene	0.70
CANCER	regulates	gene	0.70
NEURODEGENERATION	therapeutic_target	gene	0.70
SUST	associated_with	gene	0.70
AKT	therapeutic_target	gene	0.70
DEPRESSION	associated_with	gene	0.70
PTPRZ1	interacts_with	gene	0.70
CANCER	activates	gene	0.70
INFLAMMATION	associated_with	gene	0.70
CANCER	associated_with	gene	0.70
PLB-1001	inhibits	drug	0.70
AUTOPHAGY	activates	gene	0.70
PI3K	therapeutic_target	gene	0.70
OXIDATIVE STRESS	therapeutic_target	gene	0.70
ANXIETY	associated_with	gene	0.60
CANCER	treats	gene	0.60
ERK	activates	gene	0.60
P53	inhibits	gene	0.60
AMYOTROPHIC LATERAL SCLEROSIS	associated_with	gene	0.60
ERK	therapeutic_target	gene	0.60
P53	therapeutic_target	gene	0.60
ERK	regulates	gene	0.60
DIABETES MELLITUS	regulates	gene	0.60
PER	therapeutic_target	gene	0.60
APOPTOSIS	regulates	gene	0.60
ERBB2	activates	gene	0.60
RAS	activates	gene	0.60
RNA	expressed_in	gene	0.60
WNT	inhibits	gene	0.60
DNA	treats	gene	0.60
APOPTOSIS	activates	gene	0.60
GENES	activates	gene	0.60
NEURODEGENERATIVE DISEASES	associated_with	gene	0.60
COMPLEMENT	interacts_with	gene	0.60
GENES	contributes_to	gene	0.60
EPILEPSY	activates	gene	0.60
STROKE	biomarker_for	gene	0.60
MGA	associated_with	gene	0.60
AND	biomarker_for	gene	0.60
PD-L1	inhibits	gene	0.60
COMPLEMENT	regulates	gene	0.60
LZTR1	inhibits	gene	0.60
INFLAMMATION	biomarker_for	gene	0.60

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Metabolic Reprogramming to Reverse Senescence	1.000	-	Senescent cell clearance as neurodegener
HK2-Dependent Metabolic Checkpoint as the Gatekeeper of DAM	0.919	neurodegeneration	How do different microglial subtypes (DA
Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Colla	0.892	neurodegeneration	View
Optimized Temporal Window for Metabolic Boosting Therapy Det	0.879	neurodegeneration	How do different microglial subtypes (DA
TREM2 R47H Variant-Driven Metabolic Dysfunction as the Prima	0.858	neurodegeneration	How do different microglial subtypes (DA

p38α Inhibitor and PRMT1 Activator Combination to Restore Ph	0.848	neurodegeneration	What is the therapeutic window between i
HSPB1 Phosphorylation Mimetics to Promote Protective TDP-43	0.820	neurodegeneration	What is the therapeutic window between i
Ketone Utilization Index as Metabolic Flexibility Biomarker	0.819	translational neuroscience	Which metabolic biomarkers can distingui
TREM2-mTOR Co-Agonism for Metabolic Reprogramming	0.803	neurodegeneration	TREM2 agonism vs antagonism in DAM micro
TREM2 Deficiency Drives Microglial Senescence via Lipid Meta	0.800	neurodegeneration	What molecular mechanisms drive microgli
SASP-Driven Microglial Metabolic Reprogramming in Synaptic P	0.796	neurodegeneration	Senolytic therapy for age-related neurod
H3: SIRT1 Insufficiency Disconnects Metabolic Sensing from E	0.770	neurodegeneration	Investigate mechanisms of epigenetic rep
METTL3-Mediated m6A Modification of lncRNA-0021 Regulates mi	0.754	molecular neurobiology	View
TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming	0.748	neurodegeneration	Gene expression changes in aging mouse b
Metabolic NAD+ Salvage Pathway Enhancement Through NAMPT Ove	0.745	neurodegeneration	Epigenetic reprogramming in aging neuron
TREM2-SIRT1 Metabolic Senescence Circuit in Microglial Aging	0.744	neurodegeneration	Gene expression changes in aging mouse b
Metabolic Inflexibility Precedes Transcriptional Reprogrammi	0.735	neurodegeneration	What is the optimal therapeutic window f
Seed-Proximal Asymmetric Duplex Stability Confers lncRNA-002	0.733	molecular neurobiology	View
Metabolic-Support Secretome Dysfunction	0.730	neurodegeneration	Which specific factors in conditioned me
Adenosine-Astrocyte Metabolic Reset	0.730	neurodegeneration	Sleep disruption as cause and consequenc
Metabolic Switch Targeting for A1→A2 Repolarization	0.726	neurodegeneration	Astrocyte reactivity subtypes in neurode
Interfacial Lipid Mimetics to Disrupt Domain Interaction	0.723	neurodegeneration	APOE4 structural biology and therapeutic
TREM2-APOE4 Axis Drives Metabolic Inflexibility in DAM	0.720	Alzheimer's disease	-
Disease-Associated Microglia Metabolic Reprogramming	0.718	neurodegeneration	Cell type vulnerability in Alzheimers Di
TREM2-DAP12 Signalosome Enhancement — Boosting PI3K-AKT-mTOR	0.718	Alzheimer's disease	TREM2 agonism vs antagonism in DAM micro
APOE4-Specific Microglial Metabolic Rescue	0.710	-	Neuroinflammation and microglial priming
Regional TREM2-Dependent Lipid Metabolism Determines Cortica	0.710	neuroinflammation	How do regional, age, and sex-dependent
Metabolic Circuit Breaker via Lipid Droplet Modulation	0.709	neurodegeneration	Microglia-astrocyte crosstalk amplificat
TET2-Mediated Demethylation Rejuvenation Therapy	0.706	neurodegeneration	Epigenetic clocks and biological aging i
Astrocyte-Neuron Metabolic Coupling Titration	0.704	metabolic neuroscience	What determines the optimal timing and d

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (10)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Model	Status	Est. Cost
AECII-specific HMGCS2 overexpression in mouse pulmonary fibrosis	validation	idiopathic pulmonary fibrosis	0.950	C57BL/6 mice with AECII-specif	proposed	N/A
NAD depletion effects on monocyte/macrophage differentiation	exploratory	Inflammatory bowel disease	0.900	Primary mouse and human monocy	proposed	N/A
FK866 treatment in DSS-induced colitis mouse model	validation	Inflammatory bowel disease (co	0.900	DSS-induced colitis mice	proposed	N/A
MAPK pathway inhibition by QTJD through butyrate mechanism	exploratory	Mycoplasma pneumoniae pneumoni	0.900	Mouse macrophages	proposed	N/A
Ketogenic diet fat threshold analysis in wild-type mice	validation	metabolic disease	0.900	C57BL/6J wild-type mice	proposed	N/A
HMGCS2 gain-of-function in AECII lipid metabolism regulation	exploratory	idiopathic pulmonary fibrosis	0.900	human AECIIs	proposed	N/A
Ketogenic diet efficacy in diet-induced obese mice	validation	obesity, metabolic disease	0.900	C57BL/6J diet-induced obese mi	proposed	N/A
FK866 in azoxymethane/DSS colitis-associated cancer model	validation	Colitis-associated cancer	0.850	AOM/DSS-treated mice	proposed	N/A
FK866 mechanism validation in Rag1-/- mice	validation	Inflammatory bowel disease	0.850	Rag1-/- mice with DSS-induced	proposed	N/A
Microarray and single-cell RNA analysis of lipid metabolism genes	exploratory	idiopathic pulmonary fibrosis	0.850	human patients, mouse models	proposed	N/A

Related Papers (2)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Opioid-induced transcriptional reprogramming of cerebrospinal fluid immune cells [PMID:41674808]	Acharya A, Ambikan AT, Neogi U, Lamberty	Res Sq	2026	0
Siah2 is a lipid-mediated metabolic sensor in adipose tissue macrophage. [PMID:41690475]	Dang TN, Ghosh B, Panta PR, Taylor JM, K	J Lipid Res	2026	0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning MET in their description or question text

p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 P

Score: 0.848 · neurodegeneration · 2026-04-13

## Mechanistic Overview p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphorylation-M

HSPB1 Phosphorylation Mimetics to Promote Protective TDP-43 Liquid-Liquid Phase

Score: 0.820 · neurodegeneration · 2026-04-13

## Mechanistic Overview HSPB1 Phosphorylation Mimetics to Promote Protective TDP-43 Liquid-Liquid Phase Separation start

Ketone Utilization Index as Metabolic Flexibility Biomarker

Score: 0.819 · translational neuroscience · 2026-04-16

## Mechanistic Overview Ketone Utilization Index as Metabolic Flexibility Biomarker starts from the claim that modulatin

TREM2-mTOR Co-Agonism for Metabolic Reprogramming

Score: 0.803 · neurodegeneration · 2026-04-16

## Mechanistic Overview TREM2-mTOR Co-Agonism for Metabolic Reprogramming starts from the claim that modulating TREM2-mT

TREM2 Deficiency Drives Microglial Senescence via Lipid Metabolism Dysregulation

Score: 0.800 · neurodegeneration · 2026-04-22

## Mechanistic Overview TREM2 Deficiency Drives Microglial Senescence via Lipid Metabolism Dysregulation starts from the

SASP-Driven Microglial Metabolic Reprogramming in Synaptic Phagocytosis

Score: 0.796 · neurodegeneration · 2026-04-07

## Mechanistic Overview SASP-Driven Microglial Metabolic Reprogramming in Synaptic Phagocytosis starts from the claim th

H3: SIRT1 Insufficiency Disconnects Metabolic Sensing from Epigenomic Homeostasi

Score: 0.770 · neurodegeneration · 2026-04-22

## Mechanistic Overview H3: SIRT1 Insufficiency Disconnects Metabolic Sensing from Epigenomic Homeostasis starts from th

METTL3-Mediated m6A Modification of lncRNA-0021 Regulates miR-6361 Sequestration

Score: 0.754 · molecular neurobiology · 2026-04-17

## **Molecular Mechanism and Rationale** The methyltransferase-like 3 (METTL3) enzyme functions as the catalytic subuni

TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming

Score: 0.748 · neurodegeneration · 2026-04-12

**Molecular Mechanism and Rationale** The TREM2-CSF1R metabolic cross-talk hypothesis centers on the intricate molecula

Metabolic NAD+ Salvage Pathway Enhancement Through NAMPT Overexpression

Score: 0.745 · neurodegeneration · 2026-04-12

**Molecular Mechanism and Rationale** The NAD+ salvage pathway represents a critical metabolic hub in neuronal energy h

TREM2-SIRT1 Metabolic Senescence Circuit in Microglial Aging

Score: 0.744 · neurodegeneration · 2026-04-12

**Molecular Mechanism and Rationale** The TREM2-SIRT1 metabolic senescence circuit represents a critical regulatory net

Metabolic Inflexibility Precedes Transcriptional Reprogramming (NAD+/SIRT3 Axis)

Score: 0.735 · neurodegeneration · 2026-04-22

**Molecular Mechanism and Rationale** The NAD+/SIRT3 axis represents a critical regulatory hub controlling mitochondria

Seed-Proximal Asymmetric Duplex Stability Confers lncRNA-0021/miR-6361 Binding S

Score: 0.733 · molecular neurobiology · 2026-04-17

**Molecular Mechanism and Rationale** The lncRNA-0021/miR-6361 interaction represents a sophisticated regulatory mechan

Metabolic-Support Secretome Dysfunction

Score: 0.730 · neurodegeneration · 2026-04-25

Healthy astrocytes provide a balanced fuel/redox/pH composition (including lactate, glucose, pyruvate, and NAD+/NADH-rel

Adenosine-Astrocyte Metabolic Reset

Score: 0.730 · neurodegeneration · 2026-04-02

## Mechanistic Overview Adenosine-Astrocyte Metabolic Reset starts from the claim that modulating ADORA2A within the dis

MET